Top Markets
#1 Gama Token Gama Token +8.43%
#2 Palladium Network Palladium Network +5.79%
#3 Akedo Akedo +4.75%
#4 Audiera Audiera +4.11%
#5 Cross Cross +3.76%
#6 Ontology Gas Ontology Gas +3.64%
#7 Perle Perle +3.24%
#8 Velvet Velvet +3.01%
#9 Humanity Humanity +2.82%
#10 BNB Attestation Service BNB Attestation Service +2.64%
Coin of the day
Gama Token Gama Token
設定
言語
日本
通貨
USD
テーマ
Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS
株式のランク #36527
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in... Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
株価
$5.34
最終同期: 2026-08-14
時価総額
$2.59M
変化（1日）
-11.00%
変化（1年）
313.95%
国
US
取引 Jupiter Neurosciences, Inc. (JUNS)

カテゴリー

Healthcare
Jupiter Neurosciences, Inc.（JUNS）の利益
2026 時点の利益 TTM: 0
Jupiter Neurosciences, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Jupiter Neurosciences, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE